Sign in

Private company

HUMANIGEN, INC

HUMANIGEN, INC is an American pharmaceutical preparations company, incorporated in Delaware.1 It is headquartered in Short Hills, New Jersey.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersShort Hills, New Jersey1
  • Incorporated inDE2
  • Business address830 Morris Turnpike, 4Th Floor, Short Hills, Nj 070782
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-2716.9%Operating margin3
-2813.4%Net margin3
-30.1%Revenue growth, 20223

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development95¢$55.2M
  • Interest5¢$2.9M

Out of $2.5M in revenue.3 The company lost money this year.

Financial statements

Revenue43$2.5M in 2022+706% since 2020
0$1.0M$2.0M$3.0M$4.0M2020: $312.0K$312.0K20202021: $3.6M$3.6M2021+1052%2022: $2.5M$2.5M2022−30%
Operating income567843-$68.3M in 2022+263% since 2016
-$300.0M-$200.0M-$100.0M02016: -$18.8M-$18.8M20162017: -$19.0M-$19.0M2017+1%2018: -$11.3M-$11.3M2018−40%2019: -$8.9M-$8.9M2019−21%2020: -$88.2M-$88.2M2020+886%2021: -$232.8M-$232.8M2021+164%2022: -$68.3M-$68.3M2022−71%
Net income567843-$70.7M in 2022+162% since 2016
-$300.0M-$200.0M-$100.0M02016: -$27.0M-$27.0M20162017: -$22.0M-$22.0M2017−19%2018: -$12.0M-$12.0M2018−45%2019: -$10.3M-$10.3M2019−14%2020: -$89.5M-$89.5M2020+770%2021: -$236.6M-$236.6M2021+164%2022: -$70.7M-$70.7M2022−70%
Fiscal year2016201720182019202020212022
Revenue$312.0K4$3.6M3$2.5M3
Research and development$10.4M5$11.2M6$2.2M7$2.6M8$72.7M4$213.1M3$55.2M3
Operating expenses$236.4M3$70.8M3
Operating income-$18.8M5-$19.0M6-$11.3M7-$8.9M8-$88.2M4-$232.8M3-$68.3M3
Interest$131.0K5$3.1M6$852.0K7$1.3M8$1.3M4$2.3M3$2.9M3
Income tax$21.6M4
Net income-$27.0M5-$22.0M6-$12.0M7-$10.3M8-$89.5M4-$236.6M3-$70.7M3
Earnings per share-$4.043-$0.793
Earnings per share (diluted)-$4.043-$0.793
Shares (weighted, basic)58.5M shares389.2M shares3
Shares (weighted, diluted)58.5M shares389.2M shares3

Compare HUMANIGEN, INC with another company

Corporate structure

HUMANIGEN, INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of HUMANIGEN, INC

  • HUMANIGEN, INC Short Hills, New Jersey

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What HUMANIGEN, INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$10.2M3 Dec 31, 2022$70.0M3 Dec 31, 2021−85.5%

Leadership

Who has led HUMANIGEN, INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David Pritchard2012–2014
  2. Cameron Durrant2016–2022

Chair

  1. Ron Martell2015
  2. Cameron Durrant2016

Chief financial officer

  1. Jeffrey H. Cooper2012–2013
  2. Herb Cross2013–2015
  3. David L. Tousley2016–2017
  4. J. Gregory Jester2018–2019
  5. Timothy E. Morris2020–2022

Chief operating officer

  1. Timothy E. Morris2020–2022
201520202025
Board members and other officers (34)

Former names

  • KALOBIOS PHARMACEUTICALS INCJun 4, 2004 to Jul 17, 20172

Timeline

  1. Jan 8, 20248-K Entered a material agreement; Bankruptcy or receivership; New debt or obligation53
  2. Sep 14, 20238-K Executive or director change54
  3. Jul 25, 20238-K Listing notice or transfer; Executive or director change; Other events55
  4. Apr 19, 20238-K Other events56
  5. Apr 6, 20238-K Listing notice or transfer57
  6. Mar 13, 20238-K Regulation FD disclosure58
  7. Mar 2, 20238-K Other events59
  8. Feb 24, 20238-K Listing notice or transfer; Other events60
  9. Dec 22, 20228-K Entered a material agreement61
  10. Nov 14, 20228-K Results of operations62
  11. Oct 6, 20228-K Listing notice or transfer63
  12. Sep 29, 20228-K Executive or director change64
  13. Jul 5, 2016New chief executive Cameron Durrant becomes CEO12
  14. Aug 10, 2012New chief executive David Pritchard becomes CEO13

Calendar

When it reported results

  1. Nov 14, 2022Reported quarterly or annual results62
  2. Aug 12, 2022Reported quarterly or annual results65
  3. May 5, 2022Reported quarterly or annual results66
  4. Feb 28, 2022Reported quarterly or annual results67
  5. Nov 12, 2021Reported quarterly or annual results68

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

100 filings to the SEC since October 2021: 3 annual reports, 5 quarterly reports, 30 major events, 44 insider forms, 9 large holders, 9 other. The latest 20:

  1. Jan 8, 20248-K EDGAR
  2. Oct 20, 20234 EDGAR
  3. Oct 12, 202325-NSE EDGAR
  4. Sep 14, 20238-K EDGAR
  5. Aug 14, 2023NT 10-Q EDGAR
  6. Jul 25, 20238-K EDGAR
  7. May 15, 202310-Q EDGAR
  8. Apr 25, 202310-K/A AMENDMENT NO. 1 EDGAR
  9. Apr 19, 20238-K EDGAR
  10. Apr 6, 20238-K EDGAR
  11. Mar 30, 202310-K EDGAR
  12. Mar 13, 20238-K EDGAR
  13. Mar 2, 20238-K EDGAR
  14. Feb 24, 20238-K EDGAR
  15. Feb 1, 2023SC 13G/A EDGAR
  16. Dec 22, 20228-K EDGAR
  17. Nov 14, 202210-Q EDGAR
  18. Nov 14, 20228-K EDGAR
  19. Oct 6, 20228-K EDGAR
  20. Sep 29, 20228-K EDGAR

The 100 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

9 open-market trades by officers, directors and large owners since October 2021: 8 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 18, 2023Black Horse Capital Master Fund Ltd.10% ownerSale386,350$0.01$3.9KForm 4
May 20, 2022BLACK HORSE CAPITAL MANAGEMENT LLC10% ownerBuy545,488$2.23$1.2MForm 4
May 19, 2022BLACK HORSE CAPITAL MANAGEMENT LLC10% ownerBuy323,808$2.19$709.1KForm 4
May 18, 2022BLACK HORSE CAPITAL MANAGEMENT LLC10% ownerBuy173,700$1.96$340.5KForm 4
Mar 11, 2022Cheval Holdings, Ltd.10% ownerBuy1,000,000$3.00$3.0MForm 4
Mar 9, 2022Kilcoyne AdrianChief Medical OfficerBuy5,000$2.78$13.9KForm 4
Mar 8, 2022Kilcoyne AdrianChief Medical OfficerBuy7,000$2.53$17.7KForm 4
Mar 2, 2022Durrant CameronChief Executive OfficerBuy40,000$2.34$93.6KForm 4
Mar 2, 2022Jordan Edward P.Chief Commercial OfficerBuy12,500$2.32$29.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How HUMANIGEN, INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARHUMANIGEN, INC1
  • CIK0001293310
  • Employer ID (EIN)77-05572361
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address830 Morris Turnpike, 4Th Floor, Short Hills, NJ 070781
  • Phone(973) 200-31001
  • Shares outstanding119,080,135 as of May 3, 202311
  • Public float$84.0M as of Jun 30, 202274
  • On EDGAR sinceJun 4, 20041
  • Filings722 in all: 4 (233), 8-K (168), 3 (53), 10-Q (33), SC 13G/A (23), SC 13G (19), SC 13D/A (17), 424B3 (16)1
    All 47 form types

    UPLOAD (15), 10-K (11), CORRESP (11), EFFECT (11), 424B5 (9), 4/A (7), DEFA14A (7), S-8 (7), CT ORDER (6), D (6), DEF 14A (6), NT 10-Q (6), S-1/A (6), POS AM (4), S-1 (4), SC 13D (4), 10-12G/A (3), 3/A (3), PRE 14A (3), REGDEX (3), S-3 (3), 10-K/A (2), 10-Q/A (2), 25-NSE (2), 8-A12B (2), 8-K/A (2), DEF 14C (2), PRE 14C (2), 10-12G (1), 424B4 (1), 5 (1), CERT (1), CERTNAS (1), FWP (1), NT 10-K (1), PRER14A (1), PRER14C (1), S-1MEF (1), S-3/A (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2023
    Quarterly report (10-Q) May 15, 2023
    Proxy statement (DEF 14A) Apr 12, 2022
    Latest 8-K (8-K) Jan 8, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
    SEC EDGAROther events
  57. 57
  58. 58
  59. 59
    SEC EDGAROther events
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74